Copilot
Your everyday AI companion
About 4.150 results
Results near Columbus, Ohio ·
  1. COVID-19 Treatment Guidelines
    https://www.covid19treatmentguidelines.nih.gov/.../vilobelimab

    Vilobelimab | COVID-19 Treatment Guidelines

    On April 4, 2023, the FDA issued an Emergency Use Authorization for the use of vilobelimab for the treatment of COVID-19 in hospitalized adults when it is administered within 48 hours of mechanical ventilation or extracorporeal membrane oxygenation. 5.
    Feedback
  2. Nature
    https://www.nature.com/articles/s41598-024-59385-w

    The effect of immunosuppressive therapies on the endothelial

  3. People also ask
    Is vilobelimab better than a placebo?
    In the analysis that did not stratify by study site (n = 368), 28-day mortality was lower in the vilobelimab arm than in the placebo arm (54 of 177 patients [31%] vs. 77 of 191 patients [44%]), and the difference between arms was statistically significant (HR 0.67; 95% CI, 0.48–0.96; P = 0.027).

    Vilobelimab | COVID-19 Treatment Guidelines

    covid19treatmentguidelines.nih.gov
    Can vilobelimab be used during pregnancy?
    There are no data on the use of vilobelimab during pregnancy, as pregnant individuals were excluded from the PANAMO trial. There are no data on the use of vilobelimab in children. Vilobelimab is not authorized by the FDA for the treatment of COVID-19 in pediatric patients.

    Vilobelimab | COVID-19 Treatment Guidelines

    covid19treatmentguidelines.nih.gov
    Does vilobelimab reduce mortality through day 28?
    The analysis that did not stratify by site demonstrated that all-cause mortality through Day 28 was significantly lower in the vilobelimab arm than in the placebo arm. Concomitant use of corticosteroids (97%) and antithrombotic agents (98%) was high in this study population.

    Vilobelimab | COVID-19 Treatment Guidelines

    covid19treatmentguidelines.nih.gov
    What is inflarx vilobelimab?
    InflaRx’s lead product candidate, vilobelimab, is a novel, intravenously delivered, first-in-class, anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical studies in different indications.

    InflaRx Announces Positive Topline Results from the ... - Yahoo Finance

    finance.yahoo.com
    Feedback
  4. Nature
    https://www.nature.com/articles/s41579-024-01036-y

    COVID-19 drug discovery and treatment options - Nature

  5. Taylor & Francis Online
    https://www.tandfonline.com/doi/full/10.1080/14712598.2023.2235269

    Optimizing the use of vilobelimab for the treatment of COVID-19

  7. springeropen.com
    https://icm-experimental.springeropen.com/articles/10.1186/s40635-023...

    Pharmacokinetic analysis of vilobelimab, anaphylatoxin C5a and …

  8. hopkinsguides.com
    https://www.hopkinsguides.com/.../540781/all/Vilobelimab

    Vilobelimab | Johns Hopkins ABX Guide

  9. Images of Vilobelimab

    bing.com/images
    See all images
  10. Yahoo Finance
    https://finance.yahoo.com/news/inflarx-announces-positive-topline...

    InflaRx Announces Positive Topline Results from the Multiple …

  11. GlobeNewswire
    https://www.globenewswire.com/news-release/2023/11/06/2773976/0/en/...

    InflaRx Announces First Patient Dosed in Phase III Trial

  12. Drugs.com
    https://www.drugs.com/cons/vilobelimab.html

    Vilobelimab Advanced Patient Information - Drugs.com

  13. GlobeNewswire
    https://www.globenewswire.com/news-release/2023/08/30/2734224/0/en/...

    InflaRx’s Marketing Authorization Application (MAA) for …